SRPTSarepta Therapeutics, Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~6% a year FCF growth. The price demands less than its three-year revenue growth of 25% a year, expectations look modest.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What SRPT's price assumes
Sarepta Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 0.86× revenue.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 4.8%
Free cash flow yield · Biotechnology median 3.6%
- Growth the price implies
- +6.1%
Growth the price implies · The price pays for +6.1% free cash flow growth a year for a decade; revenue has grown +25% a year over the last three.
- Price / book
- 1.11
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.11
- EV / EBIToperating margin −7.3%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 0.89
- Free cash flow, trailing twelve months
- $82M
- Market capitalisation
- $1.69B
- 3-year revenue growth
- +25%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.